Similar articles for PMID: 28410143

Year	Number of Results
1997	1
1998	3
1999	1
2002	1
2004	3
2005	4
2006	1
2007	2
2009	1
2010	1
2011	2
2013	2
2014	6
2015	6
2016	8
2017	10
2018	22
2019	14
2020	11
2021	23
2022	25
2023	4
2024	0

1

Targeted radionuclide therapy: frontiers in theranostics.

Gallivanone F, Valente M, Savi A, Canevari C, Castiglioni I. Gallivanone F, et al. Front Biosci (Landmark Ed). 2017 Jun 1;22(10):1750-1759. doi: 10.2741/4569. Front Biosci (Landmark Ed). 2017. PMID: 28410143 Free article. Review.

2

Theranostic Advances in Breast Cancer in Nuclear Medicine.

Vahidfar N, Aghanejad A, Ahmadzadehfar H, Farzanehfar S, Eppard E. Vahidfar N, et al. Int J Mol Sci. 2021 Apr 27;22(9):4597. doi: 10.3390/ijms22094597. Int J Mol Sci. 2021. PMID: 33925632 Free PMC article. Review.

3

Nuclear medicine theranostics comes of age.

Herrmann K, Kraus BJ, Hadaschik B, Kunikowska J, van Poppel H, N'Dow J, Sartor O, Oyen WJG. Herrmann K, et al. Lancet Oncol. 2021 Nov;22(11):1497-1498. doi: 10.1016/S1470-2045(21)00540-4. Lancet Oncol. 2021. PMID: 34735807 No abstract available.

4

^203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer.

Li M, Sagastume EA, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, Graves S, Copping R, Mirzadeh S, Zimmerman BE, Larsen RH, Johnson FL, Schultz MK. Li M, et al. Curr Med Chem. 2020;27(41):7003-7031. doi: 10.2174/0929867327999200727190423. Curr Med Chem. 2020. PMID: 32720598 Free PMC article. Review.

5

Radioligand Theranostics in the Management of Neuroendocrine Tumors.

Harris AG, Vinik AI, OʼDorisio TM, OʼDorisio MS. Harris AG, et al. Pancreas. 2020 May/Jun;49(5):599-603. doi: 10.1097/MPA.0000000000001546. Pancreas. 2020. PMID: 32433395 Free PMC article. No abstract available.

6

Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.

Langbein T, Weber WA, Eiber M. Langbein T, et al. J Nucl Med. 2019 Sep;60(Suppl 2):13S-19S. doi: 10.2967/jnumed.118.220566. J Nucl Med. 2019. PMID: 31481583 Free article. Review.

7

Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More.

Turner JH. Turner JH. Cancer Biother Radiopharm. 2019 Apr;34(3):135-140. doi: 10.1089/cbr.2019.29006.jht. Cancer Biother Radiopharm. 2019. PMID: 30973278 No abstract available.

8

Theranostic approaches in nuclear medicine: current status and future prospects.

Filippi L, Chiaravalloti A, Schillaci O, Cianni R, Bagni O. Filippi L, et al. Expert Rev Med Devices. 2020 Apr;17(4):331-343. doi: 10.1080/17434440.2020.1741348. Epub 2020 Mar 19. Expert Rev Med Devices. 2020. PMID: 32157920 Review.

9

Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.

Miller C, Rousseau J, Ramogida CF, Celler A, Rahmim A, Uribe CF. Miller C, et al. Theranostics. 2022 Jan 1;12(1):232-259. doi: 10.7150/thno.62851. eCollection 2022. Theranostics. 2022. PMID: 34987643 Free PMC article. Review.

10

Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.

Gomes Marin JF, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, Barbosa FG, Queiroz MA, Cerri GG, Buchpiguel CA. Gomes Marin JF, et al. Radiographics. 2020 Oct;40(6):1715-1740. doi: 10.1148/rg.2020200021. Radiographics. 2020. PMID: 33001789 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

140 results

Results by year